Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors
Background ANV419 is a stable antibody–cytokine fusion protein consisting of interleukin-2 (IL-2) fused to an anti-IL-2 monoclonal antibody that sterically hinders binding of IL-2 to the α subunit of its receptor but has selective affinity for the receptor βγ subunits. Thus, ANV419 preferentially st...
Salvato in:
| Autori principali: | , , , , , , , , , , , |
|---|---|
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
BMJ Publishing Group
2023-11-01
|
| Serie: | Journal for ImmunoTherapy of Cancer |
| Accesso online: | https://jitc.bmj.com/content/11/11/e007784.full |
| Tags: |
Nessun Tag, puoi essere il primo ad aggiungerne!!
|